Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company weekly Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E13.95 EPS (ttm)3.16 Insider Own0.10% Shs Outstand1.69B Perf Week-1.08%
Market Cap74.37B Forward P/E9.90 EPS next Y4.45 Insider Trans0.11% Shs Float1.63B Perf Month-7.83%
Income5.17B PEG2.54 EPS next Q1.06 Inst Own80.20% Short Float6.81% Perf Quarter-3.82%
Sales23.29B P/S3.19 EPS this Y28.70% Inst Trans-0.06% Short Ratio8.31 Perf Half Y-10.34%
Book/sh9.31 P/B4.73 EPS next Y6.66% ROA15.10% Target Price55.63 Perf Year-22.21%
Cash/sh5.19 P/C8.49 EPS next 5Y5.50% ROE37.30% 52W Range43.81 - 63.69 Perf YTD-15.26%
Dividend1.64 P/FCF28.49 EPS past 5Y14.50% ROI25.40% 52W High-30.84% Beta0.71
Dividend %3.72% Quick Ratio1.80 Sales past 5Y6.60% Gross Margin71.10% 52W Low0.55% ATR0.85
Employees23300 Current Ratio1.90 Sales Q/Q14.00% Oper. Margin27.80% RSI (14)36.96 Volatility1.34% 1.80%
OptionableYes Debt/Eq0.40 EPS Q/Q12.90% Profit Margin22.10% Rel Volume0.97 Prev Close44.13
ShortableYes LT Debt/Eq0.37 EarningsJul 25 BMO Payout51.10% Avg Volume13.40M Price44.05
Recom2.20 SMA20-4.06% SMA50-5.12% SMA200-11.59% Volume13,061,816 Change-0.18%
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Jul-18-19 04:13PM  These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger Investor's Business Daily
12:17PM  Market-based pricing disappearing on blue-chip US loans Reuters
10:33AM  Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth Zacks
06:32AM  Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with metastatic colorectal cancer PR Newswire
06:30AM  Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer Business Wire
Jul-16-19 04:19PM  Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings? Zacks
01:15PM  Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study Zacks
07:52AM  Why Bristol-Myers Squibb Company (NYSE:BMY) Is A Financially Healthy Company Simply Wall St.
07:31AM  Jim Cramer Weighs In On Marvell, General Motors And More Benzinga
Jul-15-19 05:45PM  Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks
10:10AM  Will Bristol-Myers (BMY) Beat Estimates Again in Its Next Earnings Report? Zacks
06:00AM  Biden healthcare plan would curb drug prices, raise taxes on rich Reuters
03:16AM  Gilead to Boost Stake in Galapagos as Part of $5.1 Billion Deal Bloomberg
Jul-14-19 08:43PM  52-Week Company Lows
Jul-13-19 12:18PM  3 U.S. Stocks to Watch in July Motley Fool
10:26AM  Health companies start reporting earnings next week: Here are 3 things to keep in mind MarketWatch
Jul-12-19 11:35AM  Drug Pricing Woes Linger on Repealing Drug Rebate Proposal Zacks
11:28AM  AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC Zacks
11:10AM  Why one top exec at this $105 billion drugmaker is 'very disappointed' with Trump Yahoo Finance
10:23AM  Health Care stocks help lead Wall Street rally Yahoo Finance Video
Jul-11-19 05:06PM  Dow Jones Passes 27,000 for the 1st Time
03:34PM  Bristol-Myers (BMY) Down 11.6% YTD: What Lies Ahead in 2H19? Zacks
03:07PM  10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond InvestorPlace
03:00PM  4 Drug Stocks Getting Smashed InvestorPlace
Jul-10-19 08:41AM  Megadeals Enter Biotech Realm And 3 Other Trends To Watch In 2019 Investor's Business Daily
08:14AM  Will Patent Woes Boost Pharma Stock Megamergers Further? Zacks
06:56AM  UPDATE 1-Elliott outspends rivals as corporate activism turns to Germany Reuters
Jul-09-19 09:55AM  New Strong Sell Stocks for July 9th Zacks
05:43AM  WHO updates its essential medicines list, adds cancer and stroke drugs Reuters
Jul-08-19 05:45PM  Bristol-Myers Squibb (BMY) Stock Moves -0.26%: What You Should Know Zacks
05:05PM  AVEO Pharmaceuticals Down More Than 50% YTD: Here's Why Zacks
10:26AM  Why Bristol-Myers Squibb Stock Plunged in the First Half of 2019 Motley Fool
Jul-07-19 07:13PM  52-Week Company Lows
Jul-05-19 09:32AM  Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs Zacks
Jul-03-19 10:13AM  Will the Pharma Space Witness More Mega-Merger Deals in 2H? Zacks
Jul-02-19 03:38PM  3 Dow Jones Stocks to Buy for the Second Half InvestorPlace
Jul-01-19 05:45PM  Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know Zacks
06:21AM  Is Bristol-Myers Squibb Company's (NYSE:BMY) P/E Ratio Really That Good? Simply Wall St.
05:17AM  Bristol-Myers Squibb Completes Divestment of UPSA Business Wire
Jun-29-19 10:08PM  How Booking Holdings Inc and Other Hedge Fund Darlings Performed in Q2 Insider Monkey
10:51AM  Bulls & Bears Of The Week: AT&T, Carnival, McDonald's, Microsoft And More Benzinga
06:00AM  3 Cancer-Treatment Stocks to Buy Motley Fool
Jun-28-19 05:08PM  AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study Zacks
09:44AM  Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger Zacks
07:00AM  Almost $500 Billion of Megadeals Get Panned Instantly Bloomberg
06:59AM  Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes Business Wire
Jun-27-19 01:01PM  Draper laboratory signs 'organ-on-chip' development deal with Bristol-Myers Squibb American City Business Journals
08:51AM  Trumps America leads charge in global dealmaking Financial Times
Jun-26-19 05:40PM  The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far) Motley Fool
11:00AM  Big Pharma Has to Bet Big on M&A. Investors Dont. Bloomberg
11:00AM  AbbVie to Buy Allergan: Prescribed ETFs Zacks
09:26AM  AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal Zacks
09:22AM  The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene Zacks
Jun-25-19 05:45PM  Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
04:15PM  AbbVie + Allergan: Where Are The Synergies? Zacks
03:56PM  Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down Zacks
01:30PM  Why politicians should not savage the $63 billion Abbvie-Allergan deal Yahoo Finance
09:35AM  Company News For Jun 25, 2019 Zacks
Jun-24-19 08:06PM  Traders Still Avoiding Small Caps Investopedia -7.42%
04:55PM  What Happened in the Stock Market Today Motley Fool
04:29PM  US STOCKS-S&P 500 slips as healthcare drags, investors eye G20 summit Reuters
04:26PM  Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks
04:23PM  Why These Innovative Biotech ETFs Soaring Zacks
04:14PM  Celgene Told To Divest Blockbuster Drug And Other Bad News For Bristol Investor's Business Daily
03:51PM  Bristol-Myers Squibb Company -- Moody's: Bristol's Otezla divestiture credit negative Moody's
03:47PM  5 Top Stock Trades for Tuesday: CELG, BMY, CZR InvestorPlace
02:27PM  US STOCKS-Wall Street struggles for direction ahead of G20 summit Reuters
01:14PM  Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback Benzinga
01:12PM  US STOCKS-Wall St flat as healthcare losses limit tech gains Reuters
12:20PM  Bristol-Myers Continues to Show Bottoming Price Action on the Charts
12:03PM  Bristol-Myers Will Divest Celgene Blockbuster to Close Deal Bloomberg
11:31AM  Bristol-Myers's $74 Billion Celgene Splurge Just Got Riskier Bloomberg
11:29AM  US STOCKS-Wall St edges higher as tech gains more than offset healthcare losses Reuters
10:54AM  Bristol-Myers plans to divest Celgene's psoriasis drug Reuters
10:52AM  Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal
10:39AM  US STOCKS-Wall Street edges higher as tech offsets healthcare loss Reuters
10:04AM  To allay FTC concerns, Bristol-Myers to sell Celgene psoriasis treatment American City Business Journals
09:09AM  US STOCKS-Wall Street set to open higher with trade talks in focus Reuters
09:00AM  Bristol-Myers Squibb Stock Is Falling as Celgene Deal Is Delayed
08:14AM  UPDATE: Bristol-Myers offers update on liver cancer trial, to sell Otezla to hasten close of Celgene deal MarketWatch
07:43AM  UPDATE 2-Bristol-Myers plans to divest Celgene's psoriasis drug Reuters
07:14AM  Bristol to divest Celgene's psoriasis treatment in FTC clearance push Reuters
06:59AM  Bristol-Myers Squibb Provides Update on Pending Merger with Celgene Business Wire
06:59AM  Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma Business Wire
04:23AM  Stocks - Caesars Entertainment, Deere Rise Premarket; Spotify, Bristol-Myers Falls
Jun-22-19 09:33AM  This would be the worst-case scenario for health stocks, according to UBS MarketWatch
Jun-21-19 10:01AM  3 Big Biotechs Hold Growth Potential in Second Half of 2019 Zacks
09:07AM  Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod Zacks
08:00AM  Where Will bluebird bio Be in 1 Year? Motley Fool
Jun-20-19 09:05AM  What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them? Motley Fool
Jun-19-19 11:04AM  The Zacks Analyst Blog Highlights: Broadcom, Amgen, NVIDIA, Bristol-Myers and Restaurant Brands Zacks
09:06AM  Big Drugmakers That May Tread the M&A Path After Pfizer Zacks
09:00AM  Bristol-Myers (BMY) Upgraded to Buy: What Does It Mean for the Stock? Zacks
08:45AM  3 Reasons Why Growth Investors Shouldn't Overlook Bristol-Myers (BMY) Zacks
06:59AM  Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy Business Wire
Jun-18-19 05:45PM  Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks
02:11PM  2019 Business of Pride honorees: Bristol-Myers Squibb American City Business Journals
01:00PM  Top Analyst Reports for Broadcom, Amgen & NVIDIA Zacks
09:51AM  Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio Zacks
Jun-17-19 09:35AM  Pfizer Expands in Cancer With $10.6 Billion Deal for Array Bloomberg
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Samuels Theodore R. IIDirectorMay 16Buy47.295,000236,44027,000May 20 04:36 PM
Santiago Karen MurphyControllerMay 16Sale47.563,065145,7713,066May 20 04:37 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400373,239May 06 04:40 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0011,594025,816Apr 05 04:32 PM
Dubow AdamChief Compliance & Ethics OffiMar 10Option Exercise0.003,735018,240Mar 13 07:41 AM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00173,4190422,683Mar 13 07:40 AM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0062,2550411,547Mar 13 07:39 AM
Biondi PaulSVP, Head of Strategy & BDMar 10Option Exercise0.008,61907,860Mar 13 07:39 AM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0019,9250141,077Mar 13 07:38 AM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0026,568063,652Mar 13 07:37 AM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMar 10Option Exercise0.005,864021,343Mar 13 07:36 AM
Santiago Karen MurphyControllerMar 10Option Exercise0.003,82506,850Mar 13 07:37 AM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0045,1700558,854Mar 13 07:35 AM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,577081,508Mar 13 07:34 AM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0014,180092,626Mar 13 07:42 AM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0015,707014,501Mar 13 07:41 AM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise17.5152,884925,999392,690Mar 04 04:42 PM
LEUNG SANDRAEVP, General CounselFeb 28Option Exercise17.51169,8932,974,826634,478Mar 04 04:42 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerFeb 02Option Exercise0.004,46504,465Feb 05 04:53 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010206,117Dec 04 04:31 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM